caffeine has been researched along with Adrenocorticotropic Hormone, Inappropriate Secretion in 1 studies
Excerpt | Relevance | Reference |
---|---|---|
"Osilodrostat (LCI699) is an adrenal steroidogenesis inhibitor currently in late-phase clinical development as a potential treatment for Cushing's disease." | 2.84 | Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults. ( Armani, S; Chun, DY; Darstein, C; Einolf, HJ; Gu, H; Kulkarni, S; Sauter, N; Ting, L; Tripathi, AP; Wang, L; Zhu, B, 2017) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Armani, S | 1 |
Ting, L | 1 |
Sauter, N | 1 |
Darstein, C | 1 |
Tripathi, AP | 1 |
Wang, L | 1 |
Zhu, B | 1 |
Gu, H | 1 |
Chun, DY | 1 |
Einolf, HJ | 1 |
Kulkarni, S | 1 |
1 trial available for caffeine and Adrenocorticotropic Hormone, Inappropriate Secretion
Article | Year |
---|---|
Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults.
Topics: Adult; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochr | 2017 |